霍勇,葛均波,韩雅玲,王建安,万征,李建平,钱菊英,王斌,项美香,孙跃民,代表《急性冠状动脉综合征患者强化他汀治疗专家共识》专家组

• 1:北京大学第一医院
• 2:复旦大学附属中山医院
• 3:沈阳军区总医院
• 4:浙江大学医学院附属第二医院

摘要(Abstract)：

<正>一、制定共识的必要性1.急性冠状动脉综合征和他汀类药物:急性冠状动脉综合征(acute coronary syndrome,ACS)是一组以急性心肌缺血为共同特征的临床综合征,包括不稳定型心绞痛(UA)、非ST段抬高心肌梗死(NSTEMI)和ST段抬高心肌梗死(STEMI)[1]。ACS主要发生机制为易损斑块破裂或溃疡合并血栓形成和(或)血管痉挛,引起冠状动脉狭窄程度急剧加重或急性闭塞[2]。ACS的罪犯病变通常

关键词(KeyWords)： 急性冠状动脉综合征;强化他汀治疗;专家共识

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 霍勇,葛均波,韩雅玲,王建安,万征,李建平,钱菊英,王斌,项美香,孙跃民,代表《急性冠状动脉综合征患者强化他汀治疗专家共识》专家组

参考文献(References)：

• [1]Hamm CW,Bassand JP,Agewall S,et al.ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:The Task Force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC).Eur Heart J,2011,32:2999-3054.
• [2]Libby P.Current concepts of the pathogenesis of the acute coronary syndromes.Circulation,2001,104:365-372.
• [3]Nissen SE.Rationale for a postintervention continuum of care:insights from intravascular ultrasound.Am J Cardiol,2000,86:12H-17H.
• [4]Rioufol G,Finet G,Ginon I,et al.Multiple atherosclerotic plaque rupture in acute coronary syndrome:a three-vessel intravascular ultrasound study.Circulation,2002,106:804-808.
• [5]Perers E,Caidahl K,Herlitz J,et al.Treatment and short-term outcome in women and men with acute coronary syndromes.Int J Cardiol,2005,103:120-127.
• [6]Reiner Z,Catapano AL,De Backer G,et al.ESC/EAS Guidelines for the management of dyslipidaemias:the Task Force for the management of dyslipidaemias of the European Society of Cardiology(ESC)and the European Atherosclerosis Society(EAS).Eur Heart J,2011,32:1769-1818.
• [7]Bi Y,Gao R,Patel A,et al.Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization:results from the Clinical Pathways for Acute Coronary Syndromes in China(CPACS)study.Am Heart J,2009,157:509-516.
• [8]Steg PG,James SK,Atar D,et al.ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.Eur Heart J,2012,33:2569-2619.
• [9]O'Gara PT,Kushner FG,Ascheim DD,et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation,2013,127:e362-e425.
• [10]Levine GN,Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention.A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.J Am Coll Cardiol,2011,58:e44-e122.
• [11]Schwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:a randomized controlled trial.JAMA,2001,285:1711-1718.
• [12]Cannon CP,Braunwald E,McCabe CH,et al.Intensive versus moderate lipid lowering with statins after acute coronary syndromes.N Engl J Med,2004,350:1495-1504.
• [13]Ray KK,Cannon CP,McCabe CH,et al.Early and late benefi ts of highdose atorvastatin in patients with acute coronary syndromes:results from the PROVE IT-TIMI 22 trial.J Am Coll Cardiol,2005,46:1405-1410.
• [14]De Lemos JA,Blazing MA,Wiviott SD,et al.Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes:phase Z of the A to Z trial.JAMA,2004,292:1307-1316.
• [15]Patti G,Pasceri V,Colonna G,et al.Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention:results of the ARMYDA-ACS randomized trial.J Am Coll Cardiol,2007,49:1272-1278.
• [16]Di Sciascio G,Patti G,Pasceri V,et al.Effi cacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention:results of the ARMYDA-RECAPTURE(Atorvastatin for Reduction of Myocardial Damage During Angioplasty)Randomized Trial.J Am Coll Cardiol,2009,54:558-565.
• [17]Briguori C,Visconti G,Focaccio A,et al.Novel approaches for preventing or limiting events(Naples)II trial:impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.J Am Coll Cardiol,2009,54:2157-2163.
• [18]Yun KH,Jeong MH,Oh SK,et al.The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.Int J Cardiol,2009,137:246-251.
• [19]Winchester DE,Wen X,Xie L,et al.Evidence of pre-procedural statin therapy a meta-analysis of randomized trials.J Am Coll Cardiol,2010,56:1099-1109.
• [20]李京倡,张晓.早期阿托伐他汀强化治疗对急性冠脉综合征患者PCI术后预后的影响.中国现代医学杂志,2012,22:61-64.
• [21]Li W,Fu X,Wang Y,et al.Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention.Cardiology,2012,122:195-202.
• [22]Yu XL,Zhang HJ,Ren SD,et al.Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury.Coron Artery Dis,2011,22:87-91.
• [23]Leone AM,Rutella S,Giannico MB,et al.Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction:Statins for regeneration after acute myocardial infarction and PCI(STRAP)trial.Int J Cardiol,2008,130:457-462.
• [24]Lee SW,Hau WK,Kong SL,et al.Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naive patients:the VENUS study.Circ J,2012,76:2662-2672.
• [25]Johnson C,Waters DD,DeMicco DA,et al.Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention(post hoc analysis of the Treating to New Targets[TNT]Study).Am J Cardiol,2008,102:1312-1317.
• [26]Josan K,Majumdar SR,McAlister FA.The effi cacy and safety of intensive statin therapy:a meta-analysis of randomized trials.CMAJ,2008,178:576-584.
• [27]Cohen DE,Anania FA,Chalasani N,et al.An assessment of statin safety by hepatologists.Am J Cardiol,2006,97:77C-81C.
• [28]U.S.Food and Drug Administration web site.FDA Drug Safety Communication:Important safety label changes to cholesterollowering statin drugs.http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm Accessed February 28,2012.
• [29]McKenney JM,Davidson MH,Jacobson TA,et al.Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.Am J Cardiol,2006,97:89C-94C.
• [30]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南.中华心血管病杂志,2007,35:390-409.
• [31]Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of non-alcoholic fatty liver disease:Practice guideline by the American Association for the Study of Liver Diseases,American College of Gastroenterology,and the American Gastroenterological Association.Am J Gastroenterol,2012,107:811-826.
• [32]U.S.Food and Drug Administration web site.FDA Drug Safety Communication:New restrictions,contraindications,and dose limitations for Zocor(simvastatin)to reduce the risk of muscle injury.http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm Accessed June 16,2011.
• [33]Sakaeda T,Kadoyama K,Okuno Y.Statin-associated muscular and renal adverse events:data mining of the public version of the FDA adverse event reporting system.PLoS One,2011,6:e28124.
• [34]National Kidney Foundation.KDOQI Clinical Practice Guideline for Diabetes and CKD:2012 Update.Am J Kidney Dis,2012,60:850-886.
• [35]瑞舒伐他汀钙片说明书.核准日期:2006年12月27日,修改日期:2011年1月5日.
• [36]Ridker PM,Danielson E,Fonseca FA,et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med,2008,359:2195-2207.
• [37]Sattar N,Preiss D,Murray HM,et al.Statins and risk of incident diabetes:a collaborative meta-analysis of randomised statin trials.Lancet,2010,375:735-742.
• [38]Mihaylova B,Emberson J,Blackwell L,et al.The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease:meta-analysis of individual data from 27randomised trials.Lancet,2012,380:581-590.
• [39]Chan J,Bao WH,Fayyad R,et al.Analysis of Safety of Atorvastatin in Asian Patient Clinical Trial.Heart,2012,98(suppl 2):E316.